Pazopanib/sunitinib

  • PDF / 169,899 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 24 Downloads / 200 Views

DOWNLOAD

REPORT

1 S

Pazopanib/sunitinib Acute myocardial infarction and cardiac toxicity: case report

A 58-year-old man developed acute myocardial infarction during treatment with sunitinib for renal cell carcinoma. He additionally developed unspecified cardiac toxicity secondary to pazopanib [routes and times to reactions onsets not stated; not all outcomes stated]. The man had been diagnosed with renal cell carcinoma in September 2005 and underwent radical right nephrectomy. In April 2008, he showed bilateral lung metastasis and was scheduled to receive sunitinib 50mg every 4 weeks. In March 2015, after nearly 7 years of sunitinib initiation, radiological progression in the lungs was noted, hence dose increase to 50mg every 2 weeks was planned. However, the increased dose was not administered due to the development of acute myocardial infarction secondary to sunitinib. The man’s sunitinib dose was reduced to 37.5mg and his acute myocardial infarction later resolved. He also showed cholangitis [aetilogy unspecified] and underwent surgery. After 6 months, he was re-started on sunitinib 50mg. However, he developed cardiac toxicity and treatment with sunitinib was discontinued. As a result, he had received nivolumab. However, 3 months later, nivolumab was discontinued due to disease progression. In October 2016, he started receiving pazopanib 400mg and 600mg daily alternately and showed cardiac toxicity. As the cardiac toxicity was not significant, his dose was increased to 600mg daily. However, he showed progression of underlying disease and therapy with pazopanib was discontinued in August 2019. In November 2019, he was treated with cabozantinib and the treatment was well tolerated. Curic Z. Renal cell carcinoma-case report. Libri Oncologici 48 (Suppl. 1): 69 (plus oral presentation) abstr. S33, 2020. Available from: URL: https://hrcak.srce.hr/ index.php?show=clanak&id_clanak_jezik=353150&lang=en [abstract]

0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

803520408

Reactions 12 Dec 2020 No. 1834

Data Loading...